Workshop summary: Novel biomarkers for HIV incidence assay development

AIDS Research and Human Retroviruses

Volumn 28, Issue 6, 2012, Pages 532-539

  Sharma, Usha K ^a   Schito, Marco ^a   Welte, Alex ^b   Rousseau, Christine ^c   Fitzgibbon, Joseph ^a   Keele, Brandon ^d   Shapiro, Stuart ^a   McMichael, Andrew ^e   Burns, David N ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; EUROPIUM; GLYCOPROTEIN GP 41; GOLD NANOPARTICLE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NANOSPHERE; NEUTRALIZING ANTIBODY; PLASMA PROTEIN; PROTEIN P66; TELOMERASE; VIRUS ENVELOPE PROTEIN;

ALGORITHM; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHROMOSOME REPLICATION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; HIGH RESOLUTION MELTING ANALYSIS; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA SYSTEM; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INCIDENCE; INNATE IMMUNITY; MACROPHAGE; MASS SPECTROMETRY; MICROFLUIDIC ANALYSIS; NANOTECHNOLOGY; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PEDIGREE; POINT MUTATION; PREDICTIVE VALUE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PUBLIC HEALTH SERVICE; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; STEM CELL; STRUCTURAL GENE; T LYMPHOCYTE; TELOMERE; VIRUS CAPSID; VIRUS GENOME; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION; WORKSHOP; WORLD HEALTH ORGANIZATION;

ALGORITHMS; BIOLOGICAL MARKERS; CD4-CD8 RATIO; COST-BENEFIT ANALYSIS; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; INCIDENCE; MALE; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.); NATIONAL INSTITUTES OF HEALTH (U.S.); NEEDS ASSESSMENT; TELOMERE HOMEOSTASIS; UNITED STATES;

EID: 84861898388     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0332     Document Type: Conference Paper

References (38)

1. Bar KJ, Li H, Chamberland A, et al.: Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010;84(12):6241-6247.
2. Busch MP, Pilcher CD, Mastro TD, et al.: Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 2010;24(18):2763-2771.
3. Welte A, McWalter TA, Laeyendecker O, and Hallett TB: Using tests for recent infection to estimate incidence: Problems and prospects for HIV. Euro Surveill 2010;15: pii,19589.
4. Hallett TB: Estimating the HIV incidence rate: Recent and future developments. Curr Opin HIV AIDS 2011;6(2): 102-107.
5. Marinda ET, Hargrove J, Preiser W, et al.: Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 2010;53(4):496-499.
6. Mastro TD, Kim AA, Hallett T, et al.: Estimating HIV incidence in populations using tests for recent infection: Issues, challenges and the way forward. J HIV/AIDS Surveill Epidemiol 2010;2(7):1-14.
7. Incidence Assay Critical Path Working Group: More and better information to tackle HIV epidemics: Towards improved HIV incidence assays. PLoS Med 2011;8(6): e1001045.
8. Proceedings of the Meeting on the Development Assays to Estimate HIV Incidence: May 13-14, 2009, Chapel Hill, North Carolina. www.who.int/diagnostics
9. McWalter TA and Welte A: Relating recent infection prevalence to incidence with a sub-population of assay nonprogressors. J Math Biol 2010;60:687-710.
10. McWalter TA and Welte A: A comparison of biomarker based incidence estimators. PLoS ONE 2009;4:e7368.
11. Kassanjee R, Welte A, McWalter TA, Viljoen J, Bärnighausen T, Newell ML, and Fatti P: Calibration of BED assay for use in incidence estimation 5th IAS Conference, 2009, on HIV pathogenesis, treatment and prevention. Abstract CDB018.
12. Bärnighausen T, McWalter T, Rosner Z, Newell M-L, and Welte A: HIV incidence estimation using the BED capture enzyme immunoassay: Systematic review and sensitivity analysis. Epidemiology 2010;21:685-697.
13. A UNAIDS/WHO publication: When and how to use assays for recent infection to estimate HIV infection at a population level. 2011: www.who.int/diagnostics
14. Welte A, McWalter TA, Laeyendecker O, and Hallett TB: Using tests for recent infection to estimate incidence: Problems and prospects for HIV. EuroSurveillance 2010;15: pii = 19589.
15. Web-based tool for assay based incidence estimation www.incidence- estimation.com/page/tools.
16. Borrow P, et al.: Innate immune factors associated with HIV- 1 transmission. Curr Opin HIV AIDS 2011;6(5):341-347.
17. Borrow P, Shattock RJ, and Vyakarnam A: Innate immunity against HIV: A priority target for HIV prevention research. Retrovirology 2010;7:84.
18. McCMichael A, Borrow P, Tomaras G, et al.: The immune response during acute HIV-1 infection: Clues for vaccine development. Nat Rev Immunol 2010;10(1):11-23.
19. Crawford H, et al.: Compensatory mutation partially restores fitness and delays reversion of mutation within the immunodominant HLA-B*5703- restricted Gag epitope in chronic HIV-1 infection. J Virol 2007;81:8346-8351.
20. Feibig EW, et al.: Dynamics of HIV viremia and antibody seroconversion in plasma donors; Implications for diagnosis and staging of primary HIV infection. AIDS 2003;17:1871-1879.
21. Tomaras GD and Haynes BF: HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS 2009;4(5):373-379.
22. Yates NL, Lucas JT, Nolen T, et al.: Multiple HIV-1 specific IgG3 responses decline during acute HIV-1: Implications for detection of incident HIV Infection. AIDS 2011;25(17):2089-2097.
23. Eisenberg DT: An evolutionary review of human telomere biology: The thrifty telomere hypothesis and notes on potential adaptive paternal effects. Am J Hum Biol 2011;23(2): 149-167.
24. Rickabaugh TM, Kilpatrick RD, Hultin LE, et al.: The dual impact of HIV-1 infection and aging on naive CD4 T-cells: Additive and distinct patterns of impairment. PLoS One 2011;6(1):e16459.
25. Kouyos RD, von Wyl V, Yerly S, et al.: Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis 2011;52(4):532-539.
26. Park SY, Love TM, Nelson J, Thurston SW, Perelson AS, and Lee HY: Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS 2011;25(16):F13-F19.
27. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008;105(21):7552-7557.
28. Abrahams MR, Anderson JA, Giorgi EE, et al.: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol 2009;83:3556-3567.
29. Towler WI, James MM, Ray SC, et al.: Analysis of HIV diversity using a high-resolution melting assay. AIDS Res Hum Retroviruses 2010;26(8):913-918.
30. James M, Lei W, Musoke P, et al.: Association of HIV diversity and survival in HIV-infected Ugandan infants PLoS One 2011;6(4):e18642.
31. Cousins MM, Laeyendecker O, Beauchamp G, et al.: Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One 2011;6(11):e27211.
32. Tang S and Hewlett I: Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen. J Infect Dis 2010;201(Suppl 1):S59-S64.
33. Tang S, Zhao J, Wang A, et al.: Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection. Clin Vaccine Immunol 2010;17(8):1244-1251.
34. Pollack MG, Shenderov AD, and Fair RB: Electrowettingbased actuation of droplets for integrated microfluidics. Lab Chip 2002;2(2):96-101.
35. Sista R, Hua Z, Thwar P, et al.: Development of a digital microfluidic platform for point of care testing. Lab Chip 2008;8(12):2091-2104.
36. Hua Z, Rouse JL, Eckhardt AE, et al.: Multiplexed real-time polymerase chain reaction on a digital microfluidic platform. Anal Chem 2010;82(6):2310-2316.
37. Pollack MG, Pamula VK, Srinivasan V, and Eckhardt AE: Applications of electrowetting-based digital microfluidics in clinical diagnostics. Expert Rev Mol Diagn 2011;11(4):393-407.
38. Kassanjee R, Welte A, McWalter TA, et al.: Seroconverting blood donors as a resource for characterising and optimizing recent infection testing algorithms for incidence estimation. PLoS One 2011;6(6):e20027.